APGE files 8-K — Item 2.02 Results of Operations

What Was Filed

Apogee Therapeutics, Inc. (APGE, $5.1B market cap) filed an 8-K disclosing Item 2.02 (Results of Operations and Financial Performance) on May 11, 2026, with SEC acceptance timestamped 07:10:16 ET. The filing is linked via EDGAR accession number 000119312526215683, and was submitted concurrently with the company’s Q1 2026 10-Q filing (accession 000119312526215698). Per SEC plain-language guidelines, Item 2.02 mandates public disclosure of material operational or financial results for a completed reporting period, typically tied to an accompanying official press release.

The Disclosure

For a biotechnology firm focused on inflammatory disease biologics, this Item 2.02 filing will incorporate a press release announcing quarterly financial results and pipeline updates, per the associated GlobeNewswire headline. The company’s latest earnings history shows no reported actual EPS or revenue for Q1 2026, with consensus Wall Street estimates calling for a $1.12 per share net loss. Unlike the firm’s three prior quarterly filings, this 8-K does not include pre-reported actual financial metrics ahead of the 10-Q’s full auditable financial statements.

Cross-Referenced Prior Signals

This 8-K follows two recent waves of insider stock sales in the 90 days prior to filing: On May 8, 2026, Chief Medical Officer Carl Dambkowski executed two open-market sales totaling 5,500 shares for gross proceeds of $462,784, alongside two M-exempt share grants. On May 4, Chief Financial Officer Jane Henderson sold 2,000 shares for total gross proceeds of $164,080. Separately, as of December 31, 2025, APGE had 215 institutional holders (a 33% quarter-over-quarter increase), with total institutional holdings valued at $5.3B representing 118.7% of the company’s float; 54 new positions were initiated, 143 increased, 43 reduced, and 19 fully closed. Analyst ratings have remained static since May 1, 2026, with 15 Buy ratings and 3 Hold ratings, no changes to the distribution in the prior month.

What This Filing Does NOT Tell Us

First, the filing does not include granular line-item Q1 2026 financial data, such as gross revenue, operating expenses, or cash reserves, only referencing the accompanying press release. Second, it provides no specific details on the clinical progress of lead asset APG777, the company’s primary candidate for atopic dermatitis and COPD, despite the associated news headline noting pipeline updates. Third, the filing does not disclose updated fully diluted share outstanding counts following the March 26, 2026 public offering that raised $403M in gross proceeds, a key metric for interpreting per-share financial results.